

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
*( Not for submission under 37 CFR 1.99)*

Application Number		10723955
Filing Date		2003-11-23
First Named Inventor		CHEN, RUOPING
Art Unit		1646
Examiner Name		Li, Ruixiang
Attorney Docket Number		AREN-007CON2

**U.S.PATENTS****Remove**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

**Add****U.S.PATENT APPLICATION PUBLICATIONS****Remove**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button

**Add****FOREIGN PATENT DOCUMENTS****Remove**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button

**Add****NON-PATENT LITERATURE DOCUMENTS****Remove**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10723955
Filing Date	2003-11-23
First Named Inventor	CHEN, RUOPING
Art Unit	1646
Examiner Name	Li, Ruixiang
Attorney Docket Number	AREN-007CON2

1	Bonta et al. Prostaglandin E2 elevation of cyclic-AMP in granuloma macrophages at various stages of inflammation: relevance to anti-inflammatory and immunomodulatory functions. Prostaglandins 1981 22:95-103.	<input type="checkbox"/>
2	Brake et al. ATP receptors in sickness, pain and death. Chemistry and Biology 1996 3: 229-232.	<input type="checkbox"/>
3	Cronstein. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 1994 76: 5-13.	<input type="checkbox"/>
4	Deporter et al. Cyclic adenosine 3', 5'-monophosphate and the mechanism of action of three common anti-inflammatory drugs. Br. J. Pharmac. 1979 65: 163-165.	<input type="checkbox"/>
5	Deporter. Cyclic adenosine 3',5'-monophosphate and leucocyte chemotaxis in vivo. Br. J. Pharmac. 1977 60: 205-207.	<input type="checkbox"/>
6	Daval. Adenosine physiology and pharmacology: how about A2 receptors? Pharmacol. Ther. 1996 71: 325-335.	<input type="checkbox"/>
7	Moore et al. The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 1995 101:387-389.	<input type="checkbox"/>
8	Naik. Increased cyclic AMP-phosphodiesterase activity during inflammation and its inhibition by anti-inflammatory drugs. Eur. J. Pharmacology 1984 104: 253-259.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Ruixiang Li/	Date Considered	10/08/2010
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.